Maspin subcellular expression in wild-type and mutant TP53 gastric cancers

Table 1 Clinicopathological characteristics of gastric cancer patients

Clinicopathological parameter		Number (n = 266), n (%)
Age (yr)	≤ 60	96 (36.09)
	> 60	170 (63.91)
Gender	Male	175 (65.78)
	Female	91 (34.22)
Localization	Proximal stomach	108 (40.60)
	Middle third	47 (17.67)
	Distal third and antrum	95 (35.71)
	Diffuse localization	16 (6.02)
Macroscopic aspect (Bormann’s type)	Polypoid	21 (7.89)
	Ulcerated	62 (23.31)
	Ulcero-infiltrative	151 (56.77)
	Diffusely infiltrative	32 (12.03)
Microscopic aspect	Adenocarcinoma G1+2	75 (28.20)
	Adenocarcinoma G3	76 (28.57)
	Papillary carcinoma	10 (3.76)
	Non-mucinous poorly cohesive	53 (19.92)
	Signet ring cell carcinoma	25 (9.40)
	Diffuse micro-glandular	27 (10.15)
Budding degree (Dyscohesivity rate)	Nodular growth	34 (12.78)
	1-4 buds/HPF	17 (6.39)
	5-9 buds/HPF	50 (18.80)
	≥ 10 buds/HPF	60 (22.56)
	Diffuse growth	105 (39.47)
Associated intestinal metaplasia	Yes	87 (32.71)
	No	179 (67.29)
pT stage	pT1	22 (8.27)
	pT2	15 (5.64)
	pT3	66 (24.81)
	pT4	163 (61.28)
pN stage	pN0	53 (19.92)
	pN1	45 (16.92)
	pN2	51 (19.17)
	pN3	117 (43.99)
Dukes-MAC-like stage	T1N0	10 (3.76)
	T1N1-3	12 (4.51)
	T2N0	7 (2.63)
	T2N1-3	8 (3)
	T3N0	13 (4.89)
	T3N1-3	53 (19.93)
	T4N0	23 (8.65)
	T4N1-3	140 (52.63)

G1: Well differentiated, G2: Moderately differentiated, G3: Poorly differentiated; pT: Depth of tumor infiltration; pN: Lymph node status.

Table 2 Expression of immunohistochemical markers and frequency of TP53 gene mutations

Parameter		Number (n = 266), n (%)
Maspin expression in tumor core	Negative	39 (14.66)
	Cytoplasm	125 (46.99)
	Mixed (nucleus+cytoplasm)	85 (31.96)
	Nuclear	17 (6.39)
Maspin expression in the invasion front	Negative	21 (7.90)
	Cytoplasm	0 (0)
	Mixed (nucleus+cytoplasm)	201 (75.56)
	Nuclear	44 (16.54)
p53 – nuclear expression	Negative	40 (15.04)
	5%-50%	69 (25.94)
	> 50%	157 (59.02)
TP53 gene status	Wild-type	176 (66.17)
	Mutations	90 (33.83)

Table 3 Correlation between clinicopathological factors and p53 expression

Clinicopathological parameter		Number (n = 266)	aP53 nuclear expression (n = 266)			aP value	bTP53 gene status (n = 266)		bP value
			negative (n = 40)	10%-50%(n = 69)	> 50% (n = 157)		Wild type(n = 176)	Mutated (n = 90)
Age (yr)	≤ 60	96	15	28	53	> 0.05	70	26	> 0.05
	> 60	170	25	41	104		106	64
Localization	Proximal/middle	155	22	34	99	> 0.05	95	60	0.05
	Distal and antrum	95	15	33	47		72	23
	Diffuse localization	16	3	3	10		9	7
Microscopy	G1+2	75	9	20	46	> 0.05	43	32	> 0.05
	G3	76	14	23	39		51	25
	Papillary	10	1	2	7		5	5
	Poorly cohesive	53	5	14	34		35	18
	Signet ring cell	25	8	2	15		19	6
	Micro-glandular	27	3	8	16		23	4
Budding degree (Dyscohesivity)	Nodular	34	4	8	22	> 0.05	17	17	0.05
	≤ 5 buds/HPF	17	2	7	8		9	8
	5-9 buds/HPF	50	5	19	26		30	20
	≥ 10 buds/HPF	60	11	13	36		42	18
	Diffuse	105	18	22	65		78	27
pT stage	pT1,2	37	6	7	24	> 0.05	24	13	> 0.05
	pT3,4	229	34	62	133		152	77
pN stage	pN0	53	11	13	29	> 0.05	32	21	> 0.05
	pN1-3	213	29	56	128		144	69
Dukes-MAC-like stage	1 + 3 - T1,2N0	17	2	3	12	> 0.05	12	5	> 0.05
	2 + 4 - T1,2N1-3	20	3	3	14		11	9
	5 + 7 – T3,4N0	36	7	10	19		20	16
	6 + 8 – T3,4N1-3	193	28	53	112		133	60

G1: Well differentiated, G2: Moderately differentiated, G3: Poorly differentiated; pT: Depth of tumor infiltration; pN: Lymph node status.

Table 4 Correlation between clinicopathological factors and Maspin expression

Clinicopathological parameter		Number(n = 266)	aTumor core (n = 266)				aP value	bInvasion front (n = 266)			bP value
			Negative (n = 39)	Cytoplasm(n = 125)	Mixed (n = 85)	Nuclear (n = 17)		Negative (n = 21)	Mixed(n = 201)	Nuclear (n = 44)
Age (yr)	≤ 60	96	8	37	39	12	< 0.01	5	85	6	> 0.05
	> 60	170	31	88	46	5		16	116	38
Localization	Proximal/middle	155	21	80	44	10	> 0.05	15	117	23	0.05
	Distal and antrum	95	17	34	41	3		6	84	5
	Diffuse localization	16	1	11	0	4		0	0	16
Microscopy	G1+2	75	10	41	22	2	0.01	5	65	5	> 0.05
	G3	76	16	42	14	4		8	54	14
	Papillary	10	0	5	5	0		0	10	0
	Poorly cohesive	53	10	19	20	4		8	35	10
	Signet ring cell	25	2	1	18	4		0	16	9
	Micro-glandular	27	1	17	6	3		0	21	6
Budding degree (Dyscohesivity)	Nodular	34	5	20	9	0	< 0.05	0	34	0	> 0.05
	≤ 5 buds/HPF	17	1	10	5	1		0	14	3
	5-9 buds/HPF	50	7	25	15	3		4	41	5
	≥ 10 buds/HPF	60	18	27	13	2		7	40	13
	Diffuse	105	8	43	43	11		10	72	23
pT stage	pT1,2	37	3	21	10	3	> 0.05	0	21	16	> 0.05
	pT3,4	229	36	104	75	14		21	180	28
pN stage	pN0	53	9	19	20	5	> 0.05	3	43	7	> 0.05
	pN1-3	213	30	106	65	12		18	158	37
Dukes-MAC-like stage	1+3 - T1,2N0	17	3	11	3	0	> 0.05	0	17	0	> 0.05
	2+4 - T1,2N1-3	20	0	12	5	3		0	17	3
	5+7 – T3,4N0	36	6	12	15	3		3	24	9
	6+8 – T3,4N1-3	193	30	90	62	11		18	143	32

G1: Well differentiated, G2: Moderately differentiated, G3: Poorly differentiated; pT: Depth of tumor infiltration; pN: Lymph node status.

Table 5 Correlation between the immunohistochemical biomarkers Maspin and p53 expression, in relation to TP53 gene status

Immunohistochemical parameter		Number (n = 266)	aP53 nuclear expression (n = 266)			aP value	bTP53 gene status (n = 266)		bP value
			Negative (n = 40)	10%-50% (n = 69)	> 50% (n = 157)		Wild-type (n = 176)	Mutated (n = 90)
Maspin expression - tumor core	Negative	39	5	7	27	> 0.05	26 (14.77)	13 (14.44)		0.05
	Cytoplasm	125	19	34	72		74 (42.05)	51 (56.67)
	Nucleus	17	7	5	5		15 (8.52)	2 (2.22)
	Mixed	85	9	23	53		61 (34.66)	24 (26.67)
Maspin expression - invasion front	Negative	21	9	3	9	> 0.05	8 (4.55)	13 (14.44)		< 0.01
	Nucleus	44	14	16	14		35 (19.88)	9 (10)
	Mixed	201	17	50	134		133 (75.57)	68 (75.56)
p53– nuclear expression	Negative	40	-	-	-		30 (17.04)	10 (11.11)		> 0.05
	5%-50%	69					47 (26.71)	22 (24.44)
	> 50%	157					99 (56.25)	58 (64.45)